Novel Actinium and Radium Nanoconstructs Show Promise for Targeted Cancer Radiotherapy

Targeted alpha-particle therapy is an emerging approach to treating cancer that aims to deliver radiation precisely to tumours while sparing healthy tissue. Dr Sandra Davern from Oak Ridge National Laboratory and her colleagues are at the forefront of developing new lanthanide vanadate nanoconstructs doped with alpha-emitting radionuclides for this application. Their recent work provides key insights into the structure and properties of these novel nanomaterials, paving the way for more effective radiotherapies.

The Promise and Challenge of Targeted Alpha Therapy

Cancer remains one of the most devastating and intractable diseases, responsible for millions of deaths worldwide each year. Despite significant advances in understanding cancer biology and developing new treatments, many patients still succumb to the disease or suffer debilitating side effects from therapy. Conventional treatments like chemotherapy and external beam radiation often fail to eradicate all tumour cells while damaging surrounding healthy tissues, underscoring the urgent need for more selective and effective approaches.

Targeted alpha-particle therapy has emerged as a promising strategy to overcome these limitations. The concept is elegant in its simplicity and specificity: deliver alpha-emitting radionuclides directly to cancer cells, where the high-energy alpha particles can deposit their cell-killing energy over a short range, on the order of a few cell diameters. This enables exquisitely precise tumour targeting with minimal collateral damage to adjacent normal tissues. The approach leverages the unique properties of alpha particles – their high linear energy transfer and short path length in tissue – to achieve potent and localised therapeutic effects.

However, realising the full potential of targeted alpha therapy in the clinic requires surmounting several formidable challenges. Chief among these is developing suitable carriers to safely and efficiently ferry the radionuclides to tumour sites. The carriers must exhibit high radionuclide loading capacity and stability, prevent premature leakage of the toxic payload, and retain the decay daughter products at the target site. They should also have favourable pharmacokinetic and biodistribution profiles, enabling rapid and specific tumour accumulation with minimal uptake in healthy organs. Biocompatibility and ease of manufacturing at clinical grade and scale are additional important considerations.

Inorganic nanoparticles, particularly lanthanide-based nanomaterials, have attracted significant attention as potential carriers for targeted alpha therapy. With their rich and tuneable physical and chemical properties, these nanomaterials offer unique opportunities for multifunctionality and optimisation. However, their successful application requires a deeper understanding of how therapeutic radionuclides interact with and incorporate into these nanoparticles, and how the resulting nanoconstructs behave in complex biological environments. Bridging this knowledge gap is critical for the rational design of safer and more efficacious targeted alpha therapies.

Pioneering Studies of Lanthanide Vanadate Nanoconstructs

The research group led by Dr Sandra Davern at Oak Ridge National Laboratory is at the forefront of efforts to elucidate these fundamental structure-property relationships. Dr Davern and her interdisciplinary team have been conducting pioneering studies on novel lanthanide vanadate nanoconstructs doped with therapeutic radionuclides, including actinium-225, radium-223, and barium-133 (as a surrogate for radium-223).

In their most recent work, published in the prestigious journal ACS Nano, the researchers synthesised a diverse library of lanthanum and europium vanadate nanoconstructs incorporating the radionuclides at various doping levels. To thoroughly characterise the nanoconstructs’ structure, composition, and morphology, they employed a powerful suite of advanced techniques spanning X-ray diffraction, Raman spectroscopy, fluorescence spectroscopy, and transmission electron microscopy. This multimodal approach provided complementary and comprehensive insights into the nanoconstructs’ properties across different length scales.

One key finding was that the nanoconstructs’ phase and size could be rationally controlled by fine-tuning the lanthanide composition and radionuclide doping level. This demonstrates the versatility and tunability of these nanomaterials and suggests that their properties can be optimised for specific therapeutic applications. Interestingly, the researchers also observed that actinium-225 doping induced characteristic changes in the nanoconstructs’ fluorescence emission spectra. They hypothesise that these changes arise from lattice defects created by the radioactive decay process, and could potentially serve as a useful optical signature to monitor radionuclide incorporation and nanoconstruct integrity.

These findings showcase the power of combining rational synthesis with multimodal characterisation to gain a holistic understanding of novel nanomaterials. By systematically varying the nanoconstruct composition and probing the resulting changes in properties, Dr Davern and her team are building a valuable knowledge base to guide the design of optimised radiotherapeutic nanocarriers.

Unravelling Atomic-Scale Interactions with Molecular Dynamics Simulations

To further illuminate the atomic-scale interactions governing the nanoconstructs’ behaviour, the researchers harnessed the power of large-scale molecular dynamics simulations. Using experimentally validated force field parameters, they constructed detailed computational models of the lanthanide vanadate nanoconstructs in explicit water, and simulated the dynamic interactions between the constituent ions over biologically relevant timescales.

The simulations revealed intriguing differences in the distribution of the actinium, radium, and barium dopants within the nanoconstructs. While actinium ions tended to incorporate into the core of the nanoparticles, radium and barium ions exhibited a stronger preference for the surface. This surface localisation of radium could potentially enhance the emitted alpha radiation dose to neighbouring tumour cells but may also increase the risk of daughter product escape from the nanocarrier.

These atomic-level insights, which are difficult or impossible to obtain through experiment alone, highlight the immense value of computational modelling in nanomedicine research. By synergistically integrating experiments and simulations, Dr Davern’s team is accelerating the development of optimised nanocarriers for targeted alpha therapy.

Advancing Understanding to Enable Translation

The experimental and computational results presented in this study represent a significant advance in our fundamental understanding of therapeutic radionuclide-doped lanthanide vanadate nanoconstructs. As Dr Davern notes, this level of atomic-scale insight into how the radionuclides’ properties and concentration influence the nanoparticles’ structure and stability is essential for the rational design of more effective targeted alpha therapies.

The study also powerfully demonstrates the benefits of a multidisciplinary and multimodal approach to investigating these complex nanosystems. By combining advanced characterisation techniques with state-of-the-art molecular simulations, the team was able to obtain a comprehensive and cohesive picture of the nanoconstructs’ behaviour that would be impossible with any single method. This synergistic integration of experiments and computation is likely to become increasingly important as the field of nanomedicine continues to evolve and mature.

Future Directions and Outlook

Building on this foundation, Dr Davern and her team are eager to further optimise and translate these promising nanoconstructs for targeted alpha therapy. Key next steps include evaluating the in vitro and in vivo stability, biodistribution, and therapeutic efficacy in relevant cancer models.

The researchers also plan to explore incorporating additional functional components, such as tumour-targeting ligands and imaging tracers, to create multifunctional theranostic agents. By enabling simultaneous tumour detection, treatment, and treatment monitoring, such agents could significantly advance precision oncology.

Ultimately, Dr Davern envisions that this work will lead to the clinical development of lanthanide vanadate nanoconstructs for targeted alpha therapy of a range of cancers. She emphasises the importance of collaboration, noting that taking nanomedicines from the lab to the clinic requires a multidisciplinary team effort involving chemists, cancer biologists, medical physicists, and clinicians. The team is excited to work together with the broader community to realise the transformative potential of targeted alpha therapy. As our fundamental understanding of therapeutic radionuclide-nanoparticle interactions continues to grow, we move closer to a future where ‘smart’ radiotherapies can precisely seek and destroy tumour cells while sparing patients from debilitating side effects.